サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1676268

脂質異常症治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2025年～2033年）

Global Lipid Disorder Treatment Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

出版日
ページ情報
英文 140 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
脂質異常症治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2025年～2033年）
出版日: 2025年03月01日
発行: Value Market Research
ページ情報: 英文 140 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

脂質異常症治療の世界市場規模は、2024年の90億3,000万米ドルから2033年までには171億3,000万米ドルに成長し、2026年から2033年の予測期間中に7.37％の堅調な年間平均成長率（CAGR）を示すと予測されます。

脂質異常症治療市場は、高脂血症や心血管疾患などの脂質関連疾患の有病率の増加に牽引され、大きな成長を遂げています。ライフスタイルの変化や食習慣がコレステロール値上昇の一因となっていることから、効果的な脂質低下療法に対する需要が急増しています。同市場には、スタチン系薬剤、フィブラート系薬剤、PCSK9阻害剤などの新しいクラスの薬剤など、さまざまな治療選択肢があり、脂質レベルの管理に有効であることから人気を集めています。ドラッグ製剤やドラッグデリバリーシステムの革新は、これらの治療法の有効性を高め、ヘルスケアプロバイダーや患者にとってより魅力的なものとなっています。

さらに、予防医療を重視する傾向が強まっていることも、脂質異常症治療薬市場に影響を与えています。ヘルスケアプロバイダーが心血管疾患に関連するリスク因子の早期介入と管理に重点を置く中、薬理学的治療に加えて生活習慣の改善を組み込んだ包括的な脂質管理プログラムに対する需要が高まっています。この動向は、脂質異常症の多面的な性質に対処する統合ケアモデルの開発をヘルスケア機関に促しています。

さらに、脂質学の研究開発への注目の高まりが、脂質異常症治療市場の技術革新を促進しています。製薬会社、学術機関、ヘルスケアプロバイダー間のコラボレーションが治療手法や技術の進歩を促進し、新製品が患者の進化するニーズに確実に応えています。また、健康全般における脂質管理の重要性に対する認識が高まっていることも、市場の成長に寄与しています。まとめると、脂質異常症治療市場は、技術の進歩、予防医療への注力、患者の転帰改善へのコミットメントを特徴とし、力強い成長が見込まれています。

当社のレポートは、様々な産業や市場に関する包括的かつ実用的な洞察をお客様に提供するために綿密に作成されています。各レポートは、市場情勢を完全に理解するために、いくつかの重要な要素を含んでいます：

市場概要：定義、分類、業界の現状など、市場に関する詳細なイントロダクション。

市場促進要因：市場成長に影響を与える主な促進要因・抑制要因・機会・課題を詳細に分析します。このセクションでは、技術の進歩、規制の変更、新たな動向などの要因を検証します。

セグメンテーション分析：製品タイプ、用途、エンドユーザー、地域などの基準に基づき、市場を明確なセグメントに内訳します。この分析により、各セグメントの業績と将来性を明らかにします。

競合情勢：市場シェア、製品ポートフォリオ、戦略的イニシアティブ、財務実績など、主要市場プレイヤーの包括的評価をします。主要企業が採用する競合力学と主要戦略に関する考察を提供します。

市場予測：過去のデータと現在の市場状況に基づき、一定期間における市場規模と成長動向を予測します。これには、定量的分析と将来の市場軌跡を示すグラフ表示が含まれます。

地域分析：地域ごとの市場パフォーマンスを評価し、主要市場や地域動向を明らかにします。地域の市場力学とビジネスチャンスを理解するのに役立ちます。

新たな動向と機会：現在の市場動向と新たな市場動向、技術革新、潜在的な投資対象分野を特定します。将来の市場開拓と成長見通しに関する洞察を提供します。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 脂質異常症治療産業分析

  • イントロダクション-市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル開発動向

第5章 脂質異常症治療の世界市場分析：薬剤タイプ別

  • 概要：薬剤タイプ別
  • 過去と予測データ分析：薬剤タイプ別
  • アトルバスタチン
  • フルバスタチン
  • ロスバスタチン
  • シンバスタチン
  • プラバスタチン
  • PCSK9阻害剤
  • その他

第6章 脂質異常症治療の世界市場分析：流通チャネル別

  • 概要：流通チャネル別
  • 過去と予測データ分析：流通チャネル別
  • 小売薬局
  • 病院薬局
  • オンライン薬局

第7章 脂質異常症治療の世界市場分析：適応症別

  • 概要：適応症別
  • 過去と予測データ分析：適応症別
  • 家族性複合型高脂血症
  • 家族性アポリポ蛋白B-100欠損症
  • 家族性ベタリポ蛋白異常症
  • 家族性高トリグリセリド血症
  • 家族性ヘテロ接合性高コレステロール血症
  • その他

第8章 脂質異常症治療の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米の売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州の売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋の売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋
  • ラテンアメリカの売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカの売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ国別一覧
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ

第9章 脂質異常症治療企業の競合情勢

  • 脂質異常症治療市場の競合
  • 提携・協力・合意
  • 合併・買収
  • 新製品の上市
  • その他の開発

第10章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca
  • Merck & Co. Inc.
  • Emcure Pharmaceuticals Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Mylan N.V.
  • Kowa Pharmaceuticals America Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Sun Pharmaceuticals Industries Ltd.
  • Wockhardt Limited
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Type (USD MN)
  • Atorvastatin Market Sales By Geography (USD MN)
  • Fluvastatin Market Sales By Geography (USD MN)
  • Rosuvastatin Market Sales By Geography (USD MN)
  • Simvastatin Market Sales By Geography (USD MN)
  • Pravastatin Market Sales By Geography (USD MN)
  • PCSK9 inhibitors Market Sales By Geography (USD MN)
  • Other Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Analysis By Indication (USD MN)
  • Familial Combined Hyperlipidemia Market Sales By Geography (USD MN)
  • Familial Defective Apolipoprotein B-100 Market Sales By Geography (USD MN)
  • Familial Dysbetalipoproteinemia Market Sales By Geography (USD MN)
  • Familial Hypertriglyceridemia Market Sales By Geography (USD MN)
  • Heterozygous Familial Hypercholesterolemia Market Sales By Geography (USD MN)
  • Other Market Sales By Geography (USD MN)
  • Global Lipid Disorder Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Lipid Disorder Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Lipid Disorder Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Type
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Indication
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Type (USD MN)
  • Atorvastatin Market Sales By Geography (USD MN)
  • Fluvastatin Market Sales By Geography (USD MN)
  • Rosuvastatin Market Sales By Geography (USD MN)
  • Simvastatin Market Sales By Geography (USD MN)
  • Pravastatin Market Sales By Geography (USD MN)
  • PCSK9 inhibitors Market Sales By Geography (USD MN)
  • Other Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Global Market Analysis By Indication (USD MN)
  • Familial Combined Hyperlipidemia Market Sales By Geography (USD MN)
  • Familial Defective Apolipoprotein B-100 Market Sales By Geography (USD MN)
  • Familial Dysbetalipoproteinemia Market Sales By Geography (USD MN)
  • Familial Hypertriglyceridemia Market Sales By Geography (USD MN)
  • Heterozygous Familial Hypercholesterolemia Market Sales By Geography (USD MN)
  • Other Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis
  • Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
目次
Product Code: VMR11212596

Global Lipid Disorder Treatment Market size is anticipated to grow from USD 9.03 Billion in 2024 to USD 17.13 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 7.37% during the forecast period of 2026 to 2033.

The lipid disorder treatment market is experiencing significant growth, driven by the increasing prevalence of lipid-related conditions such as hyperlipidemia and cardiovascular diseases. As lifestyle changes and dietary habits contribute to rising cholesterol levels, the demand for effective lipid-lowering therapies is surging. The market includes a range of treatment options, including statins, fibrates, and newer classes of medications such as PCSK9 inhibitors, which are gaining traction due to their efficacy in managing lipid levels. Innovations in drug formulations and delivery systems are enhancing the effectiveness of these therapies, making them more appealing to healthcare providers and patients.

Moreover, the growing emphasis on preventive healthcare is influencing the lipid disorder treatment market. As healthcare providers focus on early intervention and management of risk factors associated with cardiovascular diseases, there is a rising demand for comprehensive lipid management programs that incorporate lifestyle modifications alongside pharmacological treatments. This trend is prompting healthcare organizations to develop integrated care models that address the multifaceted nature of lipid disorders.

Furthermore, the increasing focus on research and development in lipidology is fostering innovation in the lipid disorder treatment market. Collaborations between pharmaceutical companies, academic institutions, and healthcare providers are driving advancements in treatment methodologies and technologies, ensuring that new products meet the evolving needs of patients. The growing awareness of the importance of lipid management in overall health is also contributing to market growth. In summary, the lipid disorder treatment market is set for robust growth, characterized by technological advancements, a focus on preventive care, and a commitment to improving patient outcomes.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Drug Type

  • Atorvastatin
  • Fluvastatin
  • Rosuvastatin
  • Simvastatin
  • Pravastatin
  • Other

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Indication

  • Familial Combined Hyperlipidemia
  • Familial Defective Apolipoprotein B-100
  • Familial Dysbetalipoproteinemia
  • Familial Hypertriglyceridemia
  • Heterozygous Familial Hypercholesterolemia
  • Other
  • COMPANIES PROFILED
  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca
  • Merck & Co. Inc.
  • Emcure Pharmaceuticals Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Mylan N.V.
  • Kowa Pharmaceuticals America Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Sun Pharmaceuticals Industries Ltd.
  • Wockhardt Limited
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. LIPID DISORDER TREATMENT INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porters Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Type
    • 3.7.2 Market Attractiveness Analysis By Distribution Channel
    • 3.7.3 Market Attractiveness Analysis By Indication
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL LIPID DISORDER TREATMENT MARKET ANALYSIS BY DRUG TYPE

  • 5.1. Overview By Drug Type
  • 5.2. Historical and Forecast Data Analysis By Drug Type
  • 5.3. Atorvastatin Historic and Forecast Sales By Regions
  • 5.4. Fluvastatin Historic and Forecast Sales By Regions
  • 5.5. Rosuvastatin Historic and Forecast Sales By Regions
  • 5.6. Simvastatin Historic and Forecast Sales By Regions
  • 5.7. Pravastatin Historic and Forecast Sales By Regions
  • 5.8. PCSK9 inhibitors Historic and Forecast Sales By Regions
  • 5.9. Other Historic and Forecast Sales By Regions

6. GLOBAL LIPID DISORDER TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 6.1. Overview By Distribution Channel
  • 6.2. Historical and Forecast Data Analysis By Distribution Channel
  • 6.3. Retail Pharmacies Historic and Forecast Sales By Regions
  • 6.4. Hospital Pharmacies Historic and Forecast Sales By Regions
  • 6.5. Online Pharmacies Historic and Forecast Sales By Regions

7. GLOBAL LIPID DISORDER TREATMENT MARKET ANALYSIS BY INDICATION

  • 7.1. Overview By Indication
  • 7.2. Historical and Forecast Data Analysis By Indication
  • 7.3. Familial Combined Hyperlipidemia Historic and Forecast Sales By Regions
  • 7.4. Familial Defective Apolipoprotein B-100 Historic and Forecast Sales By Regions
  • 7.5. Familial Dysbetalipoproteinemia Historic and Forecast Sales By Regions
  • 7.6. Familial Hypertriglyceridemia Historic and Forecast Sales By Regions
  • 7.7. Heterozygous Familial Hypercholesterolemia Historic and Forecast Sales By Regions
  • 7.8. Other Historic and Forecast Sales By Regions

8. GLOBAL LIPID DISORDER TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE LIPID DISORDER TREATMENT COMPANIES

  • 9.1. Lipid Disorder Treatment Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF LIPID DISORDER TREATMENT INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Pfizer Inc.
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Novartis AG
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. AstraZeneca
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. Merck & Co. Inc.
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. Emcure Pharmaceuticals Ltd.
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. Teva Pharmaceuticals Industries Ltd.
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. Mylan N.V.
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. Kowa Pharmaceuticals America Inc.
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. Glenmark Pharmaceuticals Ltd.
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. Sun Pharmaceuticals Industries Ltd.
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments
  • 10.13. Wockhardt Limited
    • 10.13.1 Company Overview
    • 10.13.2 Company Revenue
    • 10.13.3 Products
    • 10.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies